Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

BACKGROUND: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Alan J, Carroll, William, Ciccarelli, Olga, Comi, Giancarlo, Cross, Anne, Donnelly, Alexis, Feinstein, Anthony, Fox, Robert J, Helme, Anne, Hohlfeld, Reinhard, Hyde, Robert, Kanellis, Pamela, Landsman, Douglas, Lubetzki, Catherine, Marrie, Ruth Ann, Morahan, Julia, Montalban, Xavier, Musch, Bruno, Rawlings, Sarah, Salvetti, Marco, Sellebjerg, Finn, Sincock, Caroline, Smith, Kathryn E, Strum, Jon, Zaratin, Paola, Coetzee, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Future Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688983/
https://www.ncbi.nlm.nih.gov/pubmed/34850641
http://dx.doi.org/10.1177/13524585211059766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688983/
https://www.ncbi.nlm.nih.gov/pubmed/34850641
http://dx.doi.org/10.1177/13524585211059766

Ejemplares similares